N. Anthony Coles, CEO and Chairperson at Cerevel Therapeutics Holdings, Inc. (CERE), sold 100,000 shares at $26.62 ($2.7M) on 2022-12-09, disclosed to the SEC on 2022-12-13.
Open-market sale of $2.7M CERE by CEO and Chairperson. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.62 | 44,855 | $1.2M | 44.8% |
| 2 | $26.62 | 44,855 | $1.2M | 44.8% |
| 3 | $27.09 | 5,145 | $139K | 5.2% |
| 4 | $27.09 | 5,145 | $139K | 5.2% |
| Total | $26.67 avg | 100,000 | $2.7M | 100% |
| Filing → |
| CERE | SELL | 2024-05-14 | $2.1M | — | Filing → |
| CERE | SELL | 2024-04-03 | $2.1M | — | Filing → |
| CERE | SELL | 2024-03-06 | $2.1M | — | Filing → |